AGM and Corporate Governance
Innova Captab Limited will convene its 22nd Annual General Meeting on June 29, 2026, via video conferencing in compliance with SEBI regulations and MCA circulars. The meeting will consider 10 resolutions including adoption of FY26 financial statements, reappointment of directors, and ratification of auditors. Key management changes involve the reappointment of Mr. Manoj Kumar Lohariwala as Whole-Time Director and Mr. Vinay Lohariwala as Managing Director for five-year terms with annual remuneration of ₹25 million each, alongside the reappointment of four independent directors for second terms.
Financial Performance Highlights
For FY26, Innova Captab reported strong financial results with consolidated revenue growth of 31% to ₹16.30 billion (standalone: ₹12.99 billion, +36% YoY). Profit after tax increased 10% to ₹1.41 billion despite standalone PAT declining 6% to ₹836.92 million. The company maintained a solid balance sheet position with total consolidated assets of ₹18.37 billion and equity of ₹10.91 billion. Key ratios included current ratio of 1.81 and debt-equity ratio of 0.36. The board declared an interim dividend of ₹2 per share, totaling ₹114.45 million.
Operational and Business Developments
The company restructured its operations into two consolidated business areas: CDMO Services and Products (70% of revenue, ₹11.33 billion, 23.8% growth) serving 350+ clients across 60+ countries, and Branded Generics (₹4.97 billion, 51.4% growth) with domestic distribution network of 250,000+ touchpoints. Significant capacity expansion included commissioning of the Kathua facility with ₹480+ crore investment, obtaining UK-MHRA approval for Baddi facility, and PIC/S certification for Kathua. Export contribution stood at 31.3% of total revenue at ₹5.03 billion.
Corporate Actions and Compliance
The company successfully completed its IPO with net reduction in issue costs of ₹26.67 million and resolved a GST Show Cause Notice of ₹158.14 million which was subsequently dropped by authorities. Related party transactions totaled ₹1.87 billion, including ₹132.48 million with Nugenic Pharma. The company provided ₹250 million guarantee for subsidiary borrowing facilities and maintained compliance with all SEBI LODR Regulations and Companies Act 2013 requirements. CSR expenditure exceeded requirements at ₹20.83 million against mandated ₹19.46 million.
Voting and Shareholder Information
Remote e-voting will be available through NSDL platform from June 26-28, 2026, with CS Sandhya R. Malhotra appointed as scrutinizer. The company confirmed all regulatory requirements for electronic AGM conduct have been met. Market capitalization stood at ₹3,948 crores as of March 31, 2026, with 57,224,929 equity shares outstanding. The integrated annual report has been distributed electronically to all shareholders.